Acquired aplastic anemia is an immune-mediated disease, in which T cells target hematopoietic cells; at presentation, the bone marrow is replaced by fat. It was reported that bone marrow adipocytes were negative regulators of hematopoietic microenvironment. To examine the role of adipocytes in bone marrow failure, we investigated peroxisomal proliferator-activated receptor gamma, a key transcription factor in adipogenesis, utilizing an antagonist of this factor called bisphenol-A-diglycidylester. While bisphenol-A-diglycidyl-ester inhibited adipogenesis as expected, it also suppressed T cell infiltration of bone marrow, reduced plasma inflammatory cytokines, decreased expression of multiple inflammasome genes, and ameliorated marrow failure.
Introduction
Aplastic anemia (AA) is the paradigmatic bone marrow (BM) failure syndrome in humans 1, 2 . AA behaves as an immune-mediated disease in most patients: activated cytotoxic T cells and type I cytokines destroy hematopoietic stem and progenitor cells, resulting in pancytopenia and absence of hematopoietic precursors in the BM 1, 2 . The BM of patients with AA is typically described as "empty", but in reality the hypocellular marrow space is occupied by fat, and specifically increased numbers of large adipocytes 3 . BM adipocytes in AA have been assumed to passively occupy marrow and to be metabolically inert under most physiological conditions 4 . Recently, evidence has been presented to support the notion that BM adipocytes might play a central function in regulating hematopoiesis [4] [5] [6] . Gene expression profiles suggest that mouse BM adipocytes possess a phenotype functionally distinct from extramedullary fat cells 6 : for example, inflammatory response genes, such as Tnfa, Il6, and Tgf1, are highly expressed, while expression of adipose-specific genes is low 6 . In one prominent report, pharmacological inhibition of peroxisomal proliferator-activated receptor gamma (PPARγ), a master regulator of adipogenesis, enhanced BM engraftment in mice after BM transplantation 7 .
PPARγ is a family of ligand-activated nuclear receptor transcription factors. There are two distinct isoforms, PPARγ1 and PPARγ2 [8] [9] [10] . PPARγ2 is exclusively expressed in adipose tissue, while PPARγ1 is ubiquitously expressed at lower levels in other tissues, such as skeletal muscle, liver, breast, prostate, and colon [8] [9] [10] [11] [12] . PPARγ plays a critical role in lipid metabolism but also in immune function, cell growth, differentiation, and 5 apoptosis [8] [9] [10] [11] [12] [13] [14] [15] . In particular, cells of the immune system, such as normal macrophages, dendritic cells, eosinophils, T cells, and B cells, also express PPARγ. Collectively, these findings prompted us to revisit the role of adipogenesis in BM failure and the possibility of PPARγ as a therapeutic target in AA.
In this study, we investigated the roles of bisphenol-A-diglycidyl-ester (BADGE, a PPARγ antagonist) in our AA mouse model. BADGE not only suppressed BM adipogenesis, but also inhibited T cell infiltration of BM and improved marrow inflammatory environment, eventually ameliorating pancytopenia and BM destruction. In vitro BADGE suppressed T cell activation and proliferation, and reduced T-cell cytokine secretion. We also tested the antagonist in a second immune-mediated BM failure murine model, using different strains and non-major histocompatibility (non-MHC) mismatched. Unexpectedly, we observed accumulation of BM adipocytes in genetically "fatless" mice in our marrow failure model. ) mice were purchased from the Jackson Laboratory (Bar Harbor, ME). FVB.A-ZIP/F1 (A-ZIP/F) "fatless" mice and their wild-type littermates were kindly provided by Dr. Charles Vinson (NCI, NIH). All mice were bred and maintained at NIH animal facilities under standard care and nutrition. Female mice at age of 8 to 12 weeks were used in each experiment. All animal studies were approved by the National Heart, Lung, and Blood Institute's Animal Care and Use
Committee.
AA mouse models. AA mice were generated through immune-mediated BM failure as previously described 16, 17 . Briefly, recipient CB10 mice were exposed to 5 Gy of total body irradiation (TBI). Lymph node (LN) cells were obtained from B6 donors, and infused into recipients by tail vein injection at 5.0 x 10 6 cells per mouse. Wild-type FVB and A-ZIP/F1 "fatless" AA mice were created as the CB10 AA model except that recipient FVB or A-ZIP/F "fatless" mice were irradiated at 6.8 Gy and injected with LN cells from MHC H2-matched donor DBA/1 mice at 10 x 10 6 per mouse.
Treatment of mice. PPARγ antagonists, BADGE or GW9662 (Sigma, St. Louis, MO), were dissolved in dimethyl sulfoxide (DMSO) and stored at -20°C. The aliquots were diluted with PBS to a final concentration of 10% DMSO and administrated by daily intraperitoneal injection at 30 mg/kg for BADGE or at 1 mg/kg for GW9662 from one day before experiment and continued for up to 2 weeks. In FVB AA model, some mice were injected with cyclosporine A (CsA, 50 mg/kg/day, Sigma) starting 1 hour after LN Confocal microscopy showed massive expansion of adipocytes in the BM of AA mice.
Overall BM cellularity, estimated by the density of DAPI staining (nuclear, blue color), was very low. In contrast, mice treated with PPARγ antagonists had many fewer adipocytes in the BM and much higher marrow cellularity ( Figure 1A , left). By conventional staining, the BM structure of AA mice showed extensive disruption and replacement by adipocytes, which occupied the "empty" space, whereas the BM of BADGE-or GW9662-treated mice showed less empty space and more hematopoietic cellularity ( Figure 1A , right). Blood leukocyte and platelet counts were higher in BADGE-9 treated mice compared with AA mice ( Figure 1B ). BM nucleated cell counts in both BADGE-and GW9662-treated mice were significantly higher than counts in the AA group. By flow cytometry, the frequency of Lin -cells and the absolute number of Lin -Sca1 + c-kit + (LSK) stem cells in BM were higher in BADGE-treated mice than in controls ( Figure 1C ).
To test for a dose effect of BADGE in the AA mouse model: we compared BADGE at low dose (15 mg/kg), standard dose (30 mg/kg), and high dose (60 mg/kg). Low dose BADGE had no effect, and high dose BADGE appeared to have no added activity for promotion of hematopoiesis and inhibition of BM adipogenesis, as compared to standard dose BADGE ( Figure 1D , and 1E), suggesting that an optimal dose of PPARγ antagonists is needed to inhibit BM adipogenesis.
To visualize hematopoietic stem and progenitor cells (HSPC, Figure 1F ) and megakaryocytes ( Figure 1G ) in the BM, we stained fixed sternums with anti-CD117 and anti-CD41 antibodies, respectively, followed by confocal imaging. In TBI alone mice, HSPC, megakaryocytes, and a few adipocytes were present in BM; in AA mice, the numbers of HSPCs and megakaryocytes were markedly reduced and adipocytes were abundant. In BADGE-treated mice, HSPCs and megakaryocytes were well preserved but with many fewer adipocytes, consistent with platelet counts on CBC and LSK cells in flow cytometry data. In both TBI only and BADGE-treated mice, HSPCs were distributed along the edge of the bones ( Figure 1F ). antagonists altered the immunological status of AA mice, we measured plasma cytokine levels in a multiplex assay. Insulin, an adipogenesis-related hormone, was higher in AA mice than in TBI controls; BADGE-or GW9662-treatment corrected insulin levels to normal. AA mice showed higher levels of inflammatory cytokine monocyte chemoattractant protein-1 (MCP-1) and Th1 cytokines such as IFNγ, IFNγ-induced protein 10 (IP-10), and TNFα than did TBI control mice. BADGE-or GW9662-treatment reduced plasma MCP-1 compared to levels in AA mice; BADGE reduced IFNγ and IP-10 levels, and GW9662-treatment reduced TNFα levels as well. BADGE-or GW9662-treatment tended to decrease IL-6 levels ( Figure 2A ).
We extracted RNA from whole femurs and performed PCR-based arrays, focusing on adipogenesis ( Figure 2B ) and inflammasome ( Figure 2C ) pathways (gene expression levels are presented as heat maps). Compared with AA mice, expression levels of many adipogenesis genes decreased by 3-20-fold in BADGE-treated mice. Affected genes were known PPARγ targets, pro-adipogenesis, and adipokine related genes. For example, expression levels of adipose angiotensinogen (Agt), Nrob2, Sirt1, Ncoa2, Adig, Bmp2, and Acacb were more than 5-fold lower in BADGE-treated mice. Expression of cell cycle-and proliferation-related genes E2f1 and Mapk14 increased 6-and 3-fold, respectively, perhaps reflecting active hematopoietic cell repopulation in the BM of BADGE-treated mice ( Figure 2B ). Inflammasome genes included four family members (Aim2, Ipaf, Nlrp1, and Nlrp3); BADGE only affected Ipaf, as expression levels of its components Naip1, Naip5, and Nlrc4, were reduced more than 3-fold, and no changes were observed in the genes of other inflammasome family members. Expression of inflammation-related genes including Il6, Tnfsf4, and Tnf also was markedly decreased 1 1 in the BADGE-treated group compared with control AA mice, while expression of the anti-inflammation related gene Nlrp12 (10 fold) was elevated ( Figure 2C ). Decreased Il-6 and Tnf expression at mRNA levels in treated mice was concordant with plasma protein levels ( Figure 2A ).
Gene expression levels, as determined by PCR array, were validated by immunoblot in order to confirm protein levels of PPARγ and AGT in BM. PPARγ isoform 2, an adipocyte-specific master regulator, was highly expressed in the BM of AA mice; both PPARγ isoforms 1 and 2 were greatly reduced in BADGE-treated mice, confirming that BADGE inhibited PPARγ expression in the model. AGT, one of the adipogenesis regulatory hormones and a PPARγ target protein, was not visible in TBI control CB10
mice but was present at high levels in AA mice. BADGE treatment reduced AGT protein levels ( Figure 2D ), consistent with PCR array data ( Figure 2B ). Furthermore, immunoblotting results demonstrated that T cells isolated from BM of BADGE-treated mice had decreased PPARγ protein levels than that from control AA mice ( Figure 2E ).
In order to determine whether PPARγ antagonist affected T cell populations and especially T cells infiltrating the marrow of AA mice, we performed flow cytometry of PB and nucleated cells manually flushed from the BM. In AA mice, there was massive expansion of CD8 + and CD4 + T cells in the BM as expected; in contrast, BADGE reduced the frequencies of both CD8 + and CD4 + T cells significantly while the absolute numbers of CD8 and CD4 T cells were not reduced ( Figure 3A ). In the PB of AA mice, CD8 + T cells were markedly expanded, and BADGE mainly reduced CD8 + T cell frequencies, with less effect on CD4 + T cells ( Figure 3B ). We measured expression of PPARγ antagonist not only inhibited T cell activation but also suppressed T cell proliferation ( Figure 4C ): PMA plus ionomycin promoted T cell proliferation, reflected by the multiple divisions seen using carboxyfluorescein succinimidyl ester (CFSE) signal, while BADGE prevented T cells from dividing.
To confirm the early effect of BADGE on T cell activation, we collected culture supernatants and measured cytokines. BADGE decreased levels of PMA-induced secretion of soluble CD137, IL-2, and IL-6 by T cells ( Figure 4D ).
Cytoplasmic calcium changes in T cells accompany activation by multiple signaling pathways. To investigate if inhibition of T cell activation by BADGE is related to this
process, we performed calcium flux assay. Stimulation with CD3 antibody crosslinking with streptavidin induced marked calcium flux in mouse LN cells, but pre-incubation with BADGE was inhibitory of cation shift in a dose-dependent fashion ( Figure 4E ).
The effects of BADGE on T cell activation, proliferation, and cytokine secretion were related to PPARγ expression levels. As shown in immuno-blotting, BADGE treatment decreased PPARγ in T cells in a dose-dependent fashion ( Figure 4F ). Similarly, BADGE also suppressed phospholipase C gamma 1 (PLCγ1) and nuclear factor of activated Tcells 1 (NFAT1) expression in activated T cells ( Figure 4F ). Plasma levels of insulin, MCP-1, TNFα, IL-6, and IFNγ were increased when BM failure was induced, suggesting an inflammatory microenvironment. Both BADGE and CsA decreased levels of IFNγ significantly, while BADGE also corrected insulin and IL-6 levels and tended to decrease other inflammatory cytokines such TNFα and MCP-1 ( Figure 5D ).
In vivo effect of BADGE on T cells in FVB BM
Low dose irradiation was associated with the appearance of only a few adipocytes in the BM of TBI control mice ( Figure 5E ). We anticipated adipocytes to be increased in the BM of LN-injected recipient mice due to BM destruction but surprisingly this did not occur ( Figure 5E ). In contrast, CsA-treated mice had much higher BM cellularity and also many more adipocytes in their BM compared with marrow from TBI control mice , at which toxic and inflammatory effects might be dominated. In our BM failure models, BADGE at 30 -50 mg/kg seems optimal to suppress immune reaction. Our initial intention in these experiments was to clarify the role of BM adipocytes in AA by inhibiting PPARγ signaling. However, we unexpectedly found that, while alloreactive T cell activation in response to multiple miHAs appeared to be ameliorated by PPARγ antagonism, inhibition of adipocyte formation was not a generalizable activity as related to marrow failure. Previous studies showed that PPARγ agonists inhibited T cell proliferative response and IL-2 secretion by activated T cells 9, 10, 12, 13 . However, our results indicated that PPARγ antagonists also had similar effects on T cell activation and IL-2 secretion; the antagonists directly BADGE-treated (n = 7). *, P < 0.05; **, P < 0.01. 
Methods
BM failure mouse models. Immune-mediated AA failure mice were generated as previously described 1, 2 . Briefly, recipient CB10 mice were exposed to 5 Gy of total body irradiation (TBI). On the same day, inguinal, brachial, and axillary lymph node ( 
